Scholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
February 06, 2020 07:53 ET
|
Scholar Rock
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020
January 10, 2020 07:30 ET
|
Scholar Rock
- Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy- Submitted IND application for SRK-181, a potent and selective...
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
January 09, 2020 07:30 ET
|
Scholar Rock
Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...
Scholar Rock Added to NASDAQ Biotechnology Index
December 19, 2019 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
November 19, 2019 07:30 ET
|
Scholar Rock
Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData...
Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress
November 12, 2019 07:30 ET
|
Scholar Rock
Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endAccelerated initiation of Phase 1...
Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference
November 08, 2019 08:01 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
October 02, 2019 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
September 05, 2019 07:30 ET
|
Scholar Rock
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at Upcoming Healthcare Conferences
September 04, 2019 16:30 ET
|
Scholar Rock
CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...